Cantor Fitzgerald Initiates Coverage On Aligos Therapeutics with Overweight Rating, Announces Price Target of $20

Benzinga Newsdesk www.benzinga.com Neutral 69.1%

Neg 0% Neu 69.1% Pos 0%

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Aligos Therapeutics (NASDAQ:ALGS) with a Overweight rating and announces Price Target of $20.